Renovia Inc. will continue providing effective products for pelvic floor disorders. The MedTech corporation based in Boston is innovating therapeutic and diagnostic products to treat pelvic floor disorders. Urinary incontinence is the main pelvic floor disorder that affects millions of women globally. The corporation founded by Marc closed a $ 32 million series B round on Tuesday. The MedTech company had $ 10 million venture debt that will go a long way in financing research.
Renovia has launched various products starting with Leva, their first product that received FDA approval. The Longwood Fund has joined the series B round in investing in Renovia. Longwood is a healthcare facility focused on supporting medical researches. The received funds will be used to develop and test four more diagnostic and therapeutic products. the fund will also finance development of a new generation of the leva device.
According to Marc beer, the organization is thrilled to receive support from leading healthcare investors. The investors have believed in their vision, and are working hard to help them realize it. Their vision is to provide better therapeutic and diagnoses methods. This great move will help treat millions of women suffering from pelvic floor disorders around the world.
Renovia Inc. will combine its exceptional experience with proprietary sensor technologies. Embracing technology in medicine will lead to organized data that will be used by researchers to develop new treatment options. A digital health platform will be used to store the client’s valuable data that will propel great knowledge and understanding of pelvic floor disorders. New tech-enabled treatment options will, in turn, lower the cost of treating pelvic floor disorders.
Prior to renovia and Aegerion, marc beer also served in OvaScience as a strategic consultant. He has more than 25 years’ experience in development and commercialization in biotechnology. He founded Renovia in 2016 alongside other successful biotechnicians such as Ramon Iglesias and Yolanda Lorie. He has rendered his services in several corporations such as ViaCell.
Marc Beer co-founded ViaCell in April 2000. ViaCell is a biotechnology company that specializes in gathering, preservation, and development of umbilical cord stem cells. During his tenure as the company CEO for several years, he steered strategies that led to rapid growth in the organization. Under his leadership, the company grew its employee capacity to 300 employees. Later in 2007, the organization was acquired by PerkinElmer.
While still the CEO of ViaCell he was a member of the board of directors in Erytech Pharma. He has also held various positions in Genzyme- a pharmaceutical company that is focused to develop several products to treat rare diseases around the globe. He was the vice president of global marketing in the corporation. He was responsible for overseeing the commercial launch of the company products. Learn more: https://www.linkedin.com/in/marcbeer
Pelvic floor disorder is a urinary problem that affects more than 250 million globally. Renovia Inc., a startup company, founded by Marc Beer is one of the companies developing various therapeutic and diagnostic products to fight the problem. The process is costly, and recently Beer managed to raise $42 million in the series B round. The money would help in developing more products alongside Leva device; the Boston based Medtech Company’s first product to get approval from FDA, Food, and Drugs Administration. The Series B round organized by Marc Beer received support from Ascension Ventures and Perceptive Advisors from Missouri and New York respectively.
Besides, The Longwood healthcare Fund supported the initiative.
According to Marc Beer, the significant support witnessed during the round is a clear indication that many healthcare investors embrace the idea of Renovia Inc. of treating, making a better diagnosis, and improving the lives of affected patients. Marc adds that the company intends to combine its proprietary and innovative sensor technologies to come up with a digitalised health platform. By extension, the customers would receive data informing them on new treatment methods, educating them, and helping in getting healthcare services at lower costs.
Marc Beer’s expertise in commercialization and development exceeds two decades, having worked organisations specialising in pharmaceutical, biotechnology as well as diagnostic devices. Before working with Renovia Inc., Beer held many senior positions in the medical sector. He was the founder and Chief Executive Officer of Viacell for more than seven years, a company that specialised in umbilical cord blood stem cells. He led the company in collecting and preserving and developing these blood cells from the start up to a robust commercial company with more than 300 employees. Beer earlier worked with Genzyme, a company that focused on developing treatment of diseases that are hard to diagnose and treat, better known as debilitating diseases. He also worked in the sales department of Abbot Pharmaceuticals and as the Chairman of Skulpt Inc., a company that helps athletes by identifying muscle strength and weaknesses.
Beer is the Chairs the GSGCC, Good Start Genetics Compensation Committee. Beer is also the founding Chairman and member of MNIAC, Minerva Neurosciences Inc. Audit Committee. Other boards that Marc is a member include Miami University and Graduate’s Business Advisory Council (BAC) and GSR, Graduate Studies Research, Notre Dame. Marc graduated from Miami University, Ohio with a Bsc. Degree. Marc admits that the idea of starting Renovia Inc. came after a phone call from Dr. Ray Iglesias, a gynecologist who has done pelvic floor surgery for over three decades. The surgeon shared his dream of coming up with a solution of helping the patients out of the operating room, and that is how Marc Beer started Renovia Inc.Learn more: https://patch.com/massachusetts/boston/renovias-marc-beer-raises-42m-treat-womens-health-issues
Marc Beer, through Renovia Inc., a startup he co-founded, has just made a significant contribution to the improvement of the health of women in Boston. Beer, who also founded the ViaCell, Inc. and served as its chief for seven years, has through this step demonstrated leadership. This act shows that he has not been consumed into the deep chambers of his career; the profits and loses; that he cares for the wellbeing of other people. This is not a common feat with many people who have held senior managerial positions in numerous companies. In a statement expressing his delight at being joined by the Longwood Fund for this work, Beer indeed acknowledged that he has a vision ‘to better diagnose, treat and improve the lives of millions of women affected by pelvic floor disorders’ around the world.
This donation will come in two packages; $32m for new equipment and the rest ($10m) in venture debt. Marc Beer’s contribution is set to be used for the development of material used for diagnosis and therapy to fight pelvic floor disorders which are estimated by medical researchers to affect about 250 million women in the world.
Beer, who has a lot of experience at sales and marketing management, has also excelled in research and development program management in therapeutic, surgical and in vitro diagnostic systems businesses. He has also served as a private consultant in the field of medical industry. After graduating with a Bachelors of Science in Business Administration from Miami University in Ohio, Beer grew career-wise to hold many top positions in companies doing business in the medical field. He has been a director at CytoPherx, Seaside Therapeutics LLC, Erytech Pharma Société Anonyme and Viacell companies the latest at which he also held the position of chairman. He has also served in the managerial boards, notably the Scientific and Medical Advisory Board at TxCell Promises, the Mass Life Science Board of the Commonwealth of Massachusetts as well as the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Body.
In taking this bold step, Beer has demonstrated that successful individuals need to use their expertise in not only building their companies and countries but also in giving back to society. Learn more: https://www.slideshare.net/MarcBeer
Marc Beer and his new startup company called Renovia, announced that after recently doing a $32 million Series B round, they will continue several new products that have to do with pelvic floor disorders.
The medical technology company, based in Boston, has created many different kinds of products to help people with such symptoms of pelvic disorders as urinary incontinence. 250 million women around the world have to deal with urinary incontinence. Renovia did recently get FDA approval of their first product called Leva.
What helped Renovia get through the Series B round is Longwood Fun, a medical care- investing firm. A Ascension Ventures company from Missouri and Perceptive Advisors from New York also helped Renovia get through this round. Funding the creation and testing of more diagnostic and therapeutic products including a new version of Leva came from the above companies.
Marc Beer, the CEO of Renovia, is excited by the support that he gets from medical care investors who have the same vision that he and his company of. They all want to improve the lives of millions of women that have to deal with pelvic disorders. His combines proprietary and innovative sensor technologies and form factors with a virtual health platform that inform their customers about treatment options. This should hopefully lead to more knowledge and understanding about pelvic disorders and should lead to cheaper long-term healthcare costs.
Marc Beer is 52 years old and Renovia is not the only company that he founded. He also founded Good Start Genetics.
He does have some spare time to be a member of other organizations that have nothing to do with his day job. He has been a part of Notre Dame Research Advisory and Notre Dame Research and Communications Advisory Committee.
Marc Beer attended Miami University (Ohio) and got a Bachelor of Science degree. It is not known for some reason what his major was at this university.
The first company that he was known to have founded was ViaCell. He founded it in April of 2000. This biotech firm focused on collecting, preserving and developing umbilical cord blood. When he left this organization, it had become a robust organization that would continue to thrive and grow into the future. By the time it was bought in 2007 by Perkin Elmer, it had 300 employees. It is hoped that he has the same success with his current company. Learn more: https://www.linkedin.com/in/marcbeer
Mark Beer studied at the Miami University located in Ohio graduating with a Bachelor of Science. Today, the individual is a renowned entrepreneur and philanthropist. After completing school, Beer specialized working in diagnostic, pharmaceutical, device, and biotechnology where he worked for over 25 years. During the 25 years, the individual garnered much experience in operation to thorough his career. In 2016, Beer established Renovia Inc. Shortly after starting up the business, the group underwent through the series A funding project. Among many other convergences of technology and medicine, Renovia is the most favorable and recent achievement of Mark Beer. These numerous achievements and the positions Beer held made him suitable to stand as the leader of Renovia.
The $42-million series B funding completed showed great development not just for Renovia but for Mark Beer and the entire Ohio community. Beer showed his leadership skills when he became the chief executive officer of ViaCell. The institution dealt with the development and preservation of the umbilical-cord stem cells. ViaCell later got acquired by the Perkin Elmer who had much experience in the industry. ViaCell opened doors to the public in 2005. Before getting its new possession, the organization had more than 300 employees. Mark Beer worked himself up through various leadership positions. Other posts Beer occupied include the executive vice president of global marketing. All these posts help Beer to develop much experience in diagnostic and pharmaceutical sections. The positions Beer held did not just develop his career in medicine but also gave him a chance to learn what the clients need. Therefore, the patients at Renovia have the right team of leadership in position.
Through the leadership of Mark Beer, Renovia established a product known as Leva. The commodity has a design to help women regain the health of the pelvic floor. The problem of the pelvic floor is spreading at a higher rate in the entire world. Other than Leva, the Renovia and Mark Beer are working tirelessly to invent new products to the market to fight the disease. The institution uses the Leva pelvic digital health system for women to have a quick recovery through exercise. The group uses this training product for the women to ensure that they benefit from the activities by doing them in the right manner. Other body issues appear as a result of the poor pelvic floor health and straightening. When the pelvic floor muscles are weak, you get pelvic floor disorder.
Renovia used some of its resources and funds to open up new clinical trials that began this year. The clinics will determine the effect of Leva on women who use the product when exercising as compared to those who do not use. The institution expected a turnout of over 225 women. Learn more: https://ideamensch.com/marc-beer/
Renovia’s CEO Marc Beer Raises Over $40 Million in Funding and Debt Venture
Marc Beer, the CEO of Renovia has 25 plus years of expertise in the biotechnology, diagnostics, and pharmaceutical industries. Gazette reported the beginning of October 2018 that he raised $32 million in funds and $10 million in venture debt for his new start-up company. He started the company with Ramon Iglesias and Yolanda Lorie as a medical technology entity, in 2016. Their mission is to develop diagnostic and treatment products for women diagnosed with pelvic disorders. Throughout his career, he’s started successful businesses and serves on the board of directors for companies and educational institutions.
When Beer started Renovia, he received his first round of funding from healthcare investment group, Longwood Fund. With the help of Perceptive Advisers and Ascension Ventures, he raised the second round of funding to support four of their products. In April of this year, the FDA approved a new product, Leva produced by the company. Marc told Gazette he now can improve the diagnosis and treatment for women diagnosed with the pelvic disorder. He plans to lead the development with the combination of proprietary technologies and a digital health forum.
The technologies and forum will provide educational and informative information that produces treatment options to customers. The goal is to increase understanding of the disorder that will eventually lead to reducing health care costs long term. Marc Beer explains that they designed treatments to restore pelvic health using various solutions to strengthen the muscles. He says Renovia plans to create a new generation of Leva for patients suffering from urinary contingency disorders. Pelvic floor disorder effects 250 million women and is treatable with the proper products.
Before co-finding Renovia, Marc Beer found ViaCell, a biotechnology company specializing in the development, preservation, and collection of blood stem cells. He started the business in 2000 and experienced rapid growth within seven years. By 2005, ViaCell became a public traded enterprise with 300 workers. Beer held positions with Global Marketing, Genzyme, Abbott Laboratories, Erytech Pharma, Good Start Genetics, Minerva Neurosciences, and Commonwealth of Massachusetts. His executive titles include vice president, board member director, chief executive officer, and chairman.
Marc is a Miami University graduate earning a BA in Business Science, in 1987. He has over 25 years of experience in development and commercialization in the devices, diagnostics, pharmaceutical, and biotechnology fields. While serving on the board of directors for a cancer foundation, he helped many cancer patients and their families during difficult times. Beer serves as a member of the Miami University Business Advisory Council. He served on the Graduate Studies Research and Advisory Council and the Research and Commercialization Advisory Committee at Notre Dame. Learn more: https://www1.salary.com/Marc-Beer-Salary-Bonus-Stock-Options-for-AEGERION-PHARMACEUTICALS-INC.html